Merck & Co (NYSE: MRK)‘s stock had its “outperform” rating restated by equities research analysts at Sanford C. Bernstein in a research note issued to investors on Friday, AnalystRatingsNetwork reports. They currently have a $49.00 target price on the stock. Sanford C. Bernstein’s target price would suggest a potential upside of 2.30% from the company’s current price.
Merck & Co (NYSE: MRK) traded up 0.52% on Friday, hitting $48.15. Merck & Co has a 52-week low of $38.72 and a 52-week high of $50.16. The stock’s 50-day moving average is currently $46.92. The company has a market cap of $145.4 billion and a price-to-earnings ratio of 24.44.
Merck & Co (NYSE: MRK) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.06. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $11.09 million. During the same quarter last year, the company posted $0.99 earnings per share. Merck & Co’s revenue was down 9.0% compared to the same quarter last year. Merck & Co has set its FY13 guidance at $3.45-3.55 EPS. On average, analysts predict that Merck & Co will post $3.50 earnings per share for the current fiscal year.
A number of other firms have also recently commented on MRK. Analysts at UBS AG raised their price target on shares of Merck & Co from $51.00 to $53.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Thursday, June 6th. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Wednesday, June 5th. They now have a $54.00 price target on the stock.
Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company. Merck & Co has a consensus rating of “Buy” and an average target price of $51.36.
The company also recently declared a quarterly dividend, which is scheduled for Monday, July 8th. Shareholders of record on Monday, June 17th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date of this dividend is Thursday, June 13th.
Merck & Co, Inc. (NYSE: MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.